SERD
Discovery of ZN-c5, a novel potent and oral selective estrogen receptor degrader
Samatar, A. A., et al. (2020) AACR Virtual Annual Meeting IISelective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
Patel, H. K., Bihani, T. (2018) Pharmacology & TherapeuticsPharmacokinetic and pharmacodynamic analysis of Fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
Wardell, S. E. et al. (2019) Breast Cancer Res TreatFinal overall survival: Fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial
Di Leo, A. et al. (2014) J Natl Cancer Inst.Buparlisib plus Fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Leo, A. D. et al. (2018) The Lancet Oncology
WEE1
A phase II trial of the WEE1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma
Liu, J.F. et al. (2020) Society of Gynecologic OncologySequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
Fang, Y. et al. (2019) Cancer CellDose Escalation Trial of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Gemcitabine and Radiation for Patients with Locally Advanced Pancreatic Cancer
Cuneo, K. C. et al. (2019) J of Clinical OncologyPhase II Study of WEE1 Inhibitor AZD1775 plus Carboplatin in Patients with TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
Leijen, S. et al. (2016) J of Clinical Oncology
BCL-2
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer
Lok, S. W. et al. (2019) Cancer Discovery
EGFR
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer: NEJM
Jänne, P. A. et al. (2015) New England J of Medicine